Chair's Address to Shareholders
Released
Released
Announcement PDF
HM1 AGM Presentation & Chair’s Address
26 November 2025
Hearts and Minds Investments Limited ACN 628 753 220
A: 12.04A, Chifley Tower, 2 Chifley Square, Sydney NSW 2000. | W: HM1.com.au | E: ir@hm1.com.au | P: 1300 737 760 or +61 2 9290 9600
Wednesday 26 November 2025
The Manager
ASX Market Announcements
ASX Limited
Exchange Centre
Level 27, 39 Martin Place
Sydney NSW 2000
Dear Shareholders,
Presentation and Chair’s Address at 2025 Annual General Meeting
In accordance with ASX Listing Rule 3.13.3, Hearts and Minds Investments Limited
(ASX: HM1) provides a copy of the address and presentation to be given at today’s
Annual General Meeting by HM1 Chair, Mr Chris Cuffe, on Wednesday 26 November
2025.
For and on behalf of the board,
Eryl Baron
Company Secretary
Hearts and Minds Investments Limited ACN 628 753 220
A: 12.04A, Chifley Tower, 2 Chifley Square, Sydney NSW 2000. | W: HM1.com.au | E: ir@hm1.com.au | P: 1300 737 760 or +61 2 9290 9600
2
Hearts and Minds Investment Limited
Chair’s Address at 2025 Annual General Meeting
Good afternoon and welcome to the seventh Annual General Meeting of Hearts and Minds
Investments Limited (which I will refer to as HM1 or the Company). My name is Chris Cuffe, and
I am Chair of the Company.
It is a pleasure to be holding our AGM in person. It is also wonderful to see that many of our
shareholders have joined us online via the Lumi platform. The hybrid meeting ensures as
many shareholders as possible can participate, allowing those online to listen to the live
webcast, ask questions, and submit votes. It is now past 4:00 pm, and I have been informed
that there is a quorum present, and I declare the meeting open.
I am joined today by my fellow Directors and company officers: Lorraine Berends (also Chair
of the Investment Committee), Matthew Grounds, Michael Traill, Guy Fowler, Gary Weiss, Geoff
Wilson, David Wright (also Chair of the Conference Fund Manager Selection Committee),
Richard Howes (Managing Director), Charlie Lanchester (Chief Investment Officer), Maggie
O’Neill (Chief Operating Officer) and our Company Secretary, Eryl Baron.
On behalf of the Board and management, I would like to thank you for your continued support
of HM1. I will address the Company’s financial results and charitable donations for the year
ended 30 June 2025 and touch on our recent investment performance.
Richard King from our auditors, Pitcher Partners, is also present and will be available to
address any questions relating to the audit of the Company’s financial statements.
Investment Performance
As you know, HM1 is a listed investment company established in 2018 with the combined
objective of providing a concentrated global equities portfolio of the highest conviction ideas
from respected fund managers, whilst also supporting Australian medical research
organisations. It was borne out of the investment and philanthropic vision of the Sohn Hearts
& Minds Investment Leaders Conference.
I am pleased to report that HM1’s investment performance has continued to be very strong.
The HM1 investment portfolio returned 25.5% for the year ended 30 June 2025, building on
gains made in the prior year. The current year's investment performance was primarily driven
by strong gains in Tencent Music, Coeur Mining, and Airbus from the 2024 Conference
Portfolio, alongside solid results from the Core Portfolio supported by positions in Zillow, Nvidia,
TSMC, Microsoft, Brookfield Corp, and Block.
Over the last four months since the end of the financial year, HM1’s investment performance
has continued to improve. The one-year investment performance to 31 October 2025 was up
22.6%, bringing the annualised investment performance since inception to 12.3%pa.
Hearts and Minds Investments Limited ACN 628 753 220
A: 12.04A, Chifley Tower, 2 Chifley Square, Sydney NSW 2000. | W: HM1.com.au | E: ir@hm1.com.au | P: 1300 737 760 or +61 2 9290 9600
3
Since 30 June 2024, the NTA and the share price has continued to improve, with the post-tax
NTA increasing to $3.44 ($3.71 pre-tax) on 30 June 2025, and the share price rising to $3.31 as
of the end of October. The share price has increased 11.8% in the year to 31 October 2025, and
the share price discount stands at 16% pre-tax and 7% post-tax. The Board remains confident
that sustained improvement in investment performance, our commitment to increasing fully
franked dividends, and deepening shareholder engagement will continue underpin the share
price relative to HM1’s NTA per share.
Dividends
During the financial year ended 30 June 2025, HM1 paid fully franked dividends amounting to
17 cents per share, with an interim dividend of 8.0 cents per share and a final dividend of 9.0
cents per share. We are pleased to report that the Board has resolved to increase dividends
by 0.5 cents per share every six months for the foreseeable future, subject to there being no
sustained period of investment market underperformance. Based on the current share price,
the increased annualised dividend represents a fully franked dividend yield of 5.44%.
Investment in Medical Research
In line with its philanthropic objective, HM1 provides financial contributions equivalent to 1.5%
of NTA per annum to leading Australian medical research organisations, to fund the
development of new medicines and treatments and to drive a new generation of medical
research in Australia. This is made possible by the contribution of fund managers, by the
Board of Directors and Committees and many of our service providers all working on a pro
bono basis. We sincerely thank everyone for their ongoing involvement and generosity.
During the year ended 30 June 2025, HM1 paid $9.5 million to its designated medical research
organisations and made provision for a further $1.8 million. These donated monies will be
used by the medical research organisations in pioneering research across cardiovascular
disease, neurodegeneration, diabetes, genomics, immunotherapies and paediatric medicine.
Including donations made by the HM1 owned and run, Sohn Hearts & Minds Conference,
Hearts & Minds has now donated over $83.7 million to medical research in Australia. This is a
significant contribution to the advancement of medical research in Australia. Your
shareholding in HM1 not only delivers investment returns and dividends: Your shareholding is
also making a meaningful difference to the prevention, diagnosis, and treatment of chronic
diseases for your fellow Australians. Further details on the impact of your contribution to
medical research can be found on our Impact Website: heartsandmindsgroup.com.au.
Hearts and Minds Investments Limited ACN 628 753 220
A: 12.04A, Chifley Tower, 2 Chifley Square, Sydney NSW 2000. | W: HM1.com.au | E: ir@hm1.com.au | P: 1300 737 760 or +61 2 9290 9600
4
FY25 in Review
This year brought changes to HM1’s executive leadership. We thank Paul Rayson, our
inaugural CEO for more than seven years of dedicated service and for laying the foundations
that continue to underpin HM1’s success. We also thank Brett Jollie, who served as CEO during
a key transition period and implemented a series of operational improvements.
In June 2025, we welcomed Richard Howes as Managing Director. Richard brings extensive
investment management industry experience and is well-placed and committed to leading
HM1 into its next phase with a clear focus on both performance and purpose.
On November 14 we held the 10th annual Sohn Hearts & Minds Conference, marking a decade
of bold ideas and generous giving. The conference continues to be central to both our
identity and our investment strategy. 35% of our portfolio is built upon the high conviction
ideas presented at the conference each year.
Conclusion
In conclusion, we believe that HM1 offers a compelling investment in a concentrated portfolio
of global equities recommended by a select panel of successful fund managers. The
investment returns of the portfolio are underpinned by a fully franked dividend that is paid
twice yearly to shareholders. All investment fees are waived and instead, an equivalent
amount is contributed to fund medical research in Australia. This represents a professionally
curated and managed investment in global equities that also delivers meaningful social
returns.
Annual General Meeting
ASX: HM1
November 2025
November 2025
This presentation has been prepared by Hearts and Minds Investments Limited (ABN 61 628 753 220) and is current as at 26 November 2025. Hearts and Minds Investments
Limited operates under a Corporate Authorised Representation (No. 1317870) from Quay Arktos RE Services Limited (AFSL No. 563036)
This presentation is not an offer or solicitation with respect to the purchase or sale of any financial product or investment and is qualified in its entirety by any information
memorandum and other legal documentation that may subsequently be made available. Accordingly, this presentation should not form the basis of any investment decision.
The information contained in this presentation is of a general nature only and does not purport to be complete. It does not contain all the information which would be required in
a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth). Furthermore, this presentation has been prepared
without taking into account the investment objectives, financial situation or particular needs of any individual person, or class of persons and does not constitute financial
product advice.
This presentation may contain statements, opinions, projections, forecasts and other material (forward looking statements), based on various assumptions. Those assumptions
may or may not prove to be correct and any information relating to past performance should not be relied upon as an indication of future performance. Forward-looking
statements include information concerning growth, pricing, future strategic objectives, business prospects, industry or market conditions, demand for and pricing of our
products, regulatory developments and general economic conditions. In addition, words such as “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “projects,”
“forecasts,” and future or conditional verbs such as “will,” “may,” “could,” “should,” and “would,” as well as all other statements that necessarily depend on future events, are
intended to identify forward-looking statements. Forward-looking statements are not guarantees, and they involve risks, uncertainties and assumptions. None of Hearts and
Minds Investments Limited, its respective officers, employees, agents, advisers or any other person named in this presentation makes any representation as to the accuracy or
likelihood of fulfilment of the forward looking statements or any of the assumptions upon which they are based.
This document also contains references to certain intentions, expectations and plans of Hearts and Minds Investments Limited. These intentions, expectations and plans may or
may not be achieved. They are based on certain assumptions which may not be met or on which views may differ. Past performance information in this presentation is given for
illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.
To the extent permitted by law, Hearts and Minds Investments Limited and its respective officers, employees, agents and advisers give no warranty, representation or guarantee
as to the accuracy, completeness or reliability of the information contained in this presentation. Further, none of Hearts and Minds Investments Limited or its respective officers,
employees, agents and advisers accepts, to the extent permitted by law, responsibility for any loss, claim, damages, costs or expenses arising out of, or in connection with, this
presentation. Any recipient of this presentation should independently satisfy themselves as to the accuracy of all information contained herein and seek independent financial
advice.
This presentation is provided to you strictly on a confidential basis and the information contained herein must not be reproduced or redistributed in any format without the
express written consent of Hearts and Minds Investments Limited.
Disclaimer
Hearts & Minds Investments
Page 2
HM1 Overview
Three highest conviction ideas from these
seven respected fund managers:
The highest conviction ideas from the
Sohn Hearts & Minds Investment Leaders
Conference
Typically 10-15 stocks held for 12 months
Conference Portfolio Core Portfolio
35%
65%
HM1 INVESTMENT
PORTFOLIO
3
ACCESS TO HIGH CONVICTION IDEAS – NO FEES
Highest conviction ideas from selected fund
managers; no fees, no minimum investment
2
DIVERSE PORTFOLIO
15+ different fund manager’s investment
approaches, expertise and styles
1
CONCENTRATED GLOBAL PORTFOLIO
Concentrated global portfolio of long
equity positions in 25-35 securities
4
ATTRACTIVE DIVIDEND YIELD
Currently 5.44% fully franked
5
IMPACT
1.5% of NTA donated to medical research.
Currently $10m per annum
6
CURRENTLY TRADING AT DISCOUNT TO NTA
Gain access to HM1 portfolio at 16%
discount to NTA
Hearts & Minds Investments
Page 3
The Board is targeting the payment of a consistent fully franked twice yearly dividends, subject to sufficient
cash reserves, available franking credits and prudent business practice.
*The Board of HM1 has resolved to increase dividends by 0.5 cps every 6 months for the foreseeable future subject to there being no sustained period of investment market underperformance.
**Prior to FY24, HM1 paid dividends annually. The dividend in April 2023 was 13.5 cps. For the purposes of this chart, we have allocated 7.0 cps to the FY23 financial year. Prior dividends were 12.0 cps
in April 2021 and 13.5 cps in April 2022. ^
Annualised fully franked dividend of 18.0cps divided by share price on 31 October 2025.
HM1 Dividend Policy
9.0cps
Final fully franked paid
Latest Dividend
5.4%
Fully Franked
^
Dividend Yield
Fully franked dividends since inception
Hearts & Minds Investments
Page 4
Investment Performance 1 month 6 months 1 year
3 years
per annum
Since Inception
per annum
Investment Performance 2.77% 21.21% 22.58% 17.87% 12.28%
MSCI World Accumulation (AUD) 3.29% 18.49% 23.08% 21.36% 15.71%
HM1 Investment Performance is calculated after expenses and before Australian taxes. The comparator is the MSCI World Accumulation in AUD; gross of withholding tax. Inception 14 Nov 2018.
Hearts & Minds Investments
Page 5
At 31 October 2025
HM1 Investment Performance
Core Fund Managers
Will Vicars
Caledonia Investments
Alan Pullen
Magellan Investment Partners
Nick Griffin
Munro Partners
Tom Cowan
TDM Growth Partners
Tom Naughton
Prusik Investment Mgmt (UK)
Hearts & Minds Investments
Page 6
HM1 Core Fund Managers
TSMC
TSM.NYSE
Intercontinental Exchange Ltd
ICE.NYSE
Nvidia
NVDA.NAS
Block Inc
SQ.NYSE
Amazon
AMZN.NAS
Microsoft Corporation
MSFT.NAS
Zillow Group Inc
Z.NAS
Mercado Libre
MELI.NYSE
Cameco
CCJ.NYSE
Rokt
Hearts & Minds Investments
Page 7
Top 10 Core Holdings
At 31 October 2025
Beeneet Kothari
Tekne Capital Mgmt (USA)
ACM Research Inc
Dan Loeb
Third Point (USA)
Live Nation Entertainment Inc
Emerson Moore
Ampfield Investments (USA)
Puulio
Mohammed Anjarwala
Advent Global Opportunities (USA)
Heidelberg Materials AG
Ben Hensman
Square Peg
Monday.com
Peter Rutter
Life Cycle Investment Partners (UK)
Steel Dynamics Inc
Qiao Ma
Munro Partners
TKO Group Holdings
Robert Mullin
Marathan Resources Advisors (USA)
Slb
Samir Mehta
J O Hambro Capital Mgmt (SG)
PB Fintech
Vihari Ross
Antipodes Partners
Brookdale Senior Living
Eric Wong
Stillpoint Investments (USA)
Morimatsu International Holdings
Hearts & Minds Investments
Page 8
2025 Conference Fund Managers & Stocks
Breakthrough Cancer Research
• Advancing CAR T cell treatments to the clinic
• Backing novel glioblastoma therapies
Neurogenerative Disease & Brain Health
• Developing new therapies for Alzheimer’s & MND
• Building brain banks and global research assets
Rare & Childhood Diseases
• Expanding genetic diagnosis in diverse communities
• Using big data to improve outcomes for critically ill kids
Cardiovascular Disease
• Developing the world’s first personalised risk prediction tool
$83m+ donated
Cumulative funding by HM1 and Sohn Hearts
& Minds Investment Leaders Conference
30+ projects
Breakthroughs across major diseases
10+ disease groups
Cancer, brain, rare disease & mental health
$9.5m donated
During the year ended 30 June 2025 and
made provision for a further $1.8 million
Investment in Medical Research
Hearts & Minds Investments
Page 9
Share your feedback
Discover